Provided by Tiger Fintech (Singapore) Pte. Ltd.

CANSINOBIO

25.950
-7.700-22.88%
Volume:4.89M
Turnover:134.68M
Market Cap:6.42B
PE:-16.00
High:30.800
Open:30.050
Low:25.650
Close:33.650
Loading ...

CanSino Biologics' 2024 Loss Narrows as Revenue Surges 137%

MT Newswires Live
·
27 Feb

CanSino Biologics Gets Clinical Trial Appproval from NMPA for Influenzae Type B Vaccine

MT Newswires Live
·
24 Feb

BRIEF-CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA China

Reuters
·
24 Feb

BUZZ-CanSino jumps as NMPA grants priority review status to infant vaccine application

Reuters
·
10 Feb

CanSino Biologics Combined Vaccine for Infants Gets Priority Review Status from Chinese Regulator

MT Newswires Live
·
07 Feb

Chinese Regulator Accepts CanSino Biologics' New Drug Application for Tetanus Vaccine

MT Newswires Live
·
06 Feb

BUZZ-China's CanSino climbs on forecasting narrowing loss, higher FY revenue

Reuters
·
20 Jan

CanSino Biologics Expects Narrower Attributable Loss in 2024

MT Newswires Live
·
17 Jan

CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Indonesia

MT Newswires Live
·
30 Dec 2024

CanSino Biologics Begins Trial for Tetanus, Diptheria, Acellular Pertussis Shots

MT Newswires Live
·
23 Dec 2024

CanSino Biologics Polio Vaccine Trials Gets First Patient Enrollment

MT Newswires Live
·
23 Dec 2024

CanSino Biologics' NDA for Combined Vaccine Accepted in China

MT Newswires Live
·
16 Dec 2024

Stock Track | CanSinoBIO Soars 5.18% on Positive Regulatory Update for Meningococcal Vaccine

Stock Track
·
27 Nov 2024

CanSino's Supplemental Application for Meningococcal Vaccine Accepted in China

MT Newswires Live
·
27 Nov 2024

CanSino Biologics Enrolls First Patient in Phase 1 Trial for Haemophilus Influenzae Vaccine

MT Newswires Live
·
19 Nov 2024

CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%

Simply Wall St.
·
12 Nov 2024

CanSino Biologics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
01 Nov 2024

CanSino Biologics Logs 3 Million Yuan of Net Attributable Profit for Q3

MT Newswires Live
·
29 Oct 2024

Even after rising 7.4% this past week, CanSino Biologics (HKG:6185) shareholders are still down 88% over the past three years

Simply Wall St.
·
24 Oct 2024

CanSino Biologics to Obtain Further $17 Million Grant from Bill & Melinda Gates Foundation for Polio Vaccine

MT Newswires Live
·
09 Oct 2024